医学
食管切除术
比例危险模型
危险系数
放化疗
内科学
生存分析
癌症
阶段(地层学)
存活率
食管癌
外科
数据库
置信区间
古生物学
生物
计算机科学
作者
Satoru Motoyama,Eri Maeda,Katsunori Iijima,Yusuke Sato,Shigeto Koizumi,Akiyuki Wakita,Yushi Nagaki,Hiromu Fujita,Takatoshi Yoneya,Kazuhiro Imai,Kaori Terata,Yoshihiro Minamiya,Takahiro Higashi
出处
期刊:Annals of Surgery
[Ovid Technologies (Wolters Kluwer)]
日期:2020-12-29
卷期号:276 (1): e16-e23
被引量:9
标识
DOI:10.1097/sla.0000000000004437
摘要
To determine whether esophagectomy provides a survival advantage in octogenarians with resectable thoracic esophageal cancer.Elderly patients with thoracic esophageal cancer do not always receive the full standard treatment; however, advanced age alone should not preclude the use of effective treatment that could meaningfully improve survival.We retrieved the 2008 to 2011 data from the National Database of Hospital-based Cancer Registries from the National Cancer Centerin Japan, divided the patients into a ≥75 group (75-79 years; n = 2935) and a ≥80 group (80 years or older; n = 2131), and then compared the patient backgrounds and survival curves. A multivariable Cox proportional hazards regression model was developed to compare the effects of esophagectomy and chemoradiotherapy in the 2 groups.A significantly greater percentage of patients were treated with esoph-agectomy in the ≥75 group (34.6%) than the ≥80 group (18.4%). Among patients who received esophagectomy, the 3-year survival rate was 51.1% in the ≥ 75 group and 39.0% in the ≥80 group (P < 0.001). However, among patients who received chemoradiotherapy, there was no difference in survival curve between the 2 groups (P = 0.17). Multivariable Cox proportional hazard analysis revealed that esoph-agectomy for clinical Stage ii-iii patients was significantly associated to better survival (adjusted HR: 0.731) (95%CI: 0.645-0.829, P < 0.001) in the ≥75 group but not the ≥ 80 group when compared with chemoradiotherapy.Many octogenarians do not necessarily get a survival benefit from esophagectomy. However, patients should be evaluated based on their overall health before ruling out surgery based on age alone.
科研通智能强力驱动
Strongly Powered by AbleSci AI